---
title: Increased Blood Glucose Levels After Steroid Injection
nct_id: NCT06228911
overall_status: COMPLETED
phase: NA
sponsor: Syrian Private University
study_type: INTERVENTIONAL
primary_condition: Osteoarthritis, Knee
countries: Syria
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06228911.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06228911"
ct_last_update_post_date: 2024-01-30
last_seen_at: "2026-05-12T06:34:02.684Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Increased Blood Glucose Levels After Steroid Injection

**Official Title:** Increased Blood Glucose Levels After Steroid Injection Into Osteoarthritic Knee in Diabetic Patients' Type 2

**NCT ID:** [NCT06228911](https://clinicaltrials.gov/study/NCT06228911)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 600
- **Lead Sponsor:** Syrian Private University
- **Conditions:** Osteoarthritis, Knee, Diabete Type 2
- **Start Date:** 2020-01-15
- **Completion Date:** 2023-09-15
- **CT.gov Last Update:** 2024-01-30

## Brief Summary

a sample of 600 patients diagnosed as Knee osteoarthritis injected with 40 mg triamcinolone, recorded their morning fasting blood glucose levels for 7 days before injection used as the baseline blood glucose level, which was compared with FBS levels for 14 days after steroid injection. Our study compared the differences in blood glucose changes between HbA1c \>7% and HbA1c ≤7% groups and those between insulin and non-insulin treated groups.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

Age \> 18 years, patients with knee osteoarthritis diagnosed according to American College of Rheumatology (ACR) Criteria (17), and grade1-3 in Kallgren-Laurence radiographic scale (18), whom failed to response to medical treatment including paracetamol and nonsteroidal anti-inflammatory medication, and to physical therapy, checking their blood glucose values daily.

Exclusion Criteria:

Patients who were unable to provide consent, patients had any contraindications to corticosteroids, patients who had received oral corticosteroid in the past 6 months or corticosteroid injection in the previous 3 months, patients who had no monitoring HbA1c level before injection or also whom had not monitor blood glucose levels before or after injection.
```

## Arms

- **insulin treated group** (EXPERIMENTAL)
- **non-insulin treated groups** (EXPERIMENTAL)

## Interventions

- **steroid (triamcinolone)** (DRUG) — triamcinolone is a synthetic corticosteroid medication used topically to treat various skin conditions, to relieve the discomfort of mouth sores, and by injection into joints to treat various joint conditions

## Primary Outcomes

- **high blood glucose** _(time frame: 3 years)_ — glucose increases after steroid dose
- **low blood glucose** _(time frame: 3 years)_ — glucose decreases after steroid dose

## Locations (1)

- Faculty of Medicine, Damascus University, Syria, Damascus, Syria

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.faculty of medicine, damascus university, syria|damascus||syria` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06228911.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06228911*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*